Amy Jones, MD
Hematology & Oncology · Dallas, TXNPI 1720422074
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $220 of the $245 with a category attached, or 89.8%. It is spread thinly across 8 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $130 and has fallen 82.6% since, to $23 in 2025. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 12 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Deciphera Pharmaceuticals Inc.$52
- Merck$50
- AbbVie$40
- Astellas Pharma US Inc$26
- Pfizer$25
- Intera Oncology, Inc$22
- plus $30 from 2 others
What the payments were for
- Food & beverage$22090%
- Education$2510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Deciphera Pharmaceuticals Inc. | 2 | $52 |
| Merck | 3 | $50 |
| AbbVie | 2 | $40 |
| Astellas Pharma US Inc | 1 | $26 |
| Pfizer | 1 | $25 |
| Intera Oncology, Inc | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $16 |
| Foundation Medicine, Inc. | 1 | $14 |
How this compares
$245 in reported general payments places this provider in the 15th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErivedgeVismodegib | 12 | $177,073 |
| Octreotide Acetate | 12 | $1,611 |
| Ondansetron Hcl | 16 | $210 |
| Prochlorperazine Maleate | 17 | $185 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.